Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00296
|
|||||
| Drug Name |
Zidovudine
|
|||||
| Synonyms |
1-(3-Azido-2,3-dideoxy-beta-D-ribofuranosyl)thymine; 3′-Azido-3′-deoxythymidine; 3' Azido 2',3' Dideoxythymidine; 3' Azido 3' deoxythymidine; 3'-Azido-2',3'-Dideoxythymidine; 3'-Azido-3'-deoxythymidine; 3'-Azido-3'-deoxythymidine & Concanavalin A; 3'-Azido-3'-deoxythymidine & Erythropoietin; 3'-Azido-3'-deoxythymidine & Heteropolyoxotungstate PM-19; 3'-Azido-3'-deoxythymidine & Interleukin-1; 3'-Azido-3'-deoxythymidine & Interleukin-2; 3'-Azido-3'-deoxythymidine & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lithium & Erythropoietin; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-1; 3'-Azido-3'-deoxythymidine & Lithium & Interleukin-6; 3'-Azido-3'-deoxythymidine & Lymphoblastoid Interferon; 3'-Azido-3'-deoxythymidine & Sho-Saiko-To; 3'-Azido-3'-deoxythymidine (AIDS); 3'-Azido-3'deoxythymidine & Interferon-alpha; 3'-Azidothymidine; 3'-Deoxy-3'-azidothymidine; 3'-azido-3'-deoxythymidine, AZT; 3-Azido-3-deoxythymidine; AZT; AZT & CD4(178)-PE 40; AZT & Colony-stimulating factor 2; AZT & Concanavalin A (ConA); AZT & EPO; AZT & GM-CSF; AZT & HPA; AZT & IFN-alpha; AZT & IL-1; AZT & IL-2; AZT & IL-6; AZT & Interferon-.alpha.-2; AZT & Li & EPO; AZT & Li & GM-CSF; AZT & Li & IL-1; AZT & Li & IL-6; AZT & Lymphoblastoid Interferon; AZT & NP (from PHCA or HSA); AZT & PM-19; AZT & SST; AZT & rIFN.alpha.2; AZT & rsCD4 & rIFN.alpha.A; AZT & rsT4; AZT & sCD4; AZT & srCD4; AZT (Antiviral); AZT Antiviral; AZT TRANSPLACENTAL CARCINOGENESIS STUDY; AZT+PRO 140; AZT, Antiviral; Antiviral; Antiviral AZT; Apo-Zidovudine; Azidodeoxythymidine; Azidothymidine; Aztec; BW A509U; BW-A 509U; BW-A-509U; BW-A509U; BWA 509U; BWA-509U; BWA509U; Cpd S; DRG-0004; DS-4152 & AZT; Interferon AD + 3'-azido-3'-deoxythymidine; Intron A & AZT; K7 [P Ti2 W10 O40]; Liposomal AZT-SN-1; Liposomal AZT-SN-3; Met-SDF-1.beta. & AZT; Met-SDF-1.beta. & Zidovudine; Novo-Azt; PC-SOD+AZT;RIFN-beta seron & AZT; Propolis+AZT; Racemic Liposomal AZT; Racemic-dipalmitoylglycerophospho-AZT (in a lipid vesicle); Retrovir; Retrovir (TN); Retrovir(TM); Retrovis (TN); SN-1-dipalmitoylglycerophospho-AZT (in a lipid vesicle); SN-3-dipalmitoylglycerophospho-AZT (in a lipid vesicle); ZDV; ZIDOVUDINE [AZT]; ZVD; Zidovudin; Zidovudina; Zidovudina [Spanish]; Zidovudine (JAN/USP/INN); Zidovudine EP III; Zidovudine [USAN:INN:BAN:JAN]; Zidovudine+PRO 140; Zidovudinum; Zidovudinum [Latin]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Human immunodeficiency virus infection [ICD11:1C62.Z] | Approved | [1] | |||
| Therapeutic Class |
Anti-HIV Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C10H13N5O4
|
|||||
| Canonical SMILES |
CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-]
|
|||||
| InChI |
InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1
|
|||||
| InChIKey |
HBOMLICNUCNMMY-XLPZGREQSA-N
|
|||||
| CAS Number |
CAS 30516-87-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 267.24 | Topological Polar Surface Area | 93.2 | ||
| Heavy Atom Count | 19 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
0
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11335699
,11360938
,11364242
,11366804
,11369366
,11372752
,11373842
,11377528
,11461910
,11484570
,11488743
,11491322
,11492147
,11495162
,12013681
,12146009
,14799161
,595886
,596433
,596437
,596594
,596595
,597291
,597292
,597293
,597457
,597458
,597459
,597460
,597461
,597462
,597463
,597555
,597641
,597664
,597665
,600904
,601536
,602048
,622272
,624122
,643735
,644084
,7846195
,7847479
,7980906
,8149829
,8173993
,855980
,9419
|
|||||
| ChEBI ID |
CHEBI:10110
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [3] | ||
| MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [2] | ||
| OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [4] | ||
| OAT2 | Transporter Info | Organic anion transporter 2 | Substrate | [4] | ||
| OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [4] | ||
| OAT4 | Transporter Info | Organic anion transporter 4 | Substrate | [4] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [5] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OAT1 | Transporter Info | Km =45.9 microM | Proximal tubule (S2) cells-OAT1 | [4] | |
| OAT2 | Transporter Info | Km =26.8 microM | Proximal tubule (S2) cells-OAT2 | [4] | ||
| OAT3 | Transporter Info | Km =145 microM | Proximal tubule (S2) cells-OAT3 | [4] | ||
| OAT4 | Transporter Info | Km =152 microM | Proximal tubule (S2) cells-OAT4 | [4] | ||
| References | ||||||
| 1 | Zidovudine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
| 3 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
| 4 | Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. | |||||
| 5 | The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.